Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany.
CONCLUSION: Direct and indirect costs associated with HSCT are substantial for patients with ALL, DLBCL and FL. Novel therapies that reduce HSCT use could reduce medical costs.
PMID: 30517020 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | General Medicine | Germany Health | Leukemia | Lymphoma | Pediatrics | Stem Cell Therapy | Stem Cells | Transplants